Study of 5 vaccines in Iran shows Sputnik V provides best protection against Covid-19 - RDIF
MOSCOW. July 7 (Interfax) - The Russian two-dose Sputnik V vaccine provides the best protection against coronavirus, the press service for the Russian Direct Investment Fund (RDIF) said following a study of five different coronavirus vaccines conducted in Iran.
The study analyzed data from around 3,600 medical students who were fully vaccinated with Sputnik V, the AstraZeneca and Sinopharm vaccines, and also the vaccines of India's Bharat Biotech and Iran's COVIran Barrekat in March-August 2021, the report said.
The study showed that Sputnik V demonstrated the best results in protection against Covid-19. The share of participants who contracted coronavirus was 3.13% of the total number vaccinated with the Russian vaccine (against 4.23% for Sinopharm and 6.22% for AstraZeneca).
The press service noted that, thanks to active cooperation between RDIF and the Iran regulatory bodies, Sputnik V was registered in Iran in January 2021 and played an important role in protecting the population from coronavirus. Iran has also approved the use of the one-dose Sputnik Light vaccine, which is the first component of Sputnik V.
RDIF is the main investor in the development and production of the Sputnik V and Sputnik Light vaccines. Sputnik V has been approved for use in 71 countries with a total population of more than four billion people, and Sputnik Light has been approved in more than 30 countries. The safety and efficacy of these vaccines have been confirmed by more than 50 studies and vaccination data from more than ten countries.